Explore the Agenda
7:30 am Check In & Morning Coffee
8:20 am Chair’s Opening Remarks
Advances in European Precision Medicine Trials & Adoption Initiatives Enabling Transformative Patient Selection & Real-World Monitoring Impact
8:30 am The Rise of Precision Medicine & Diagnostics
- An introduction to BIVDA, BIVDA working parties, and how BIVDA is supporting the delivery of the NHS 10-year plan and the Government’s Life Science Strategy
- The role diagnostics will play in delivering the NHS 3 shifts (Hospital to Community, Analogue to Digital, Treatment to Prevention)
- Creating a roadmap from innovation to adoption in the NHS
8:50 am Session Reserved for Foundation Medicine
Presentation details to be announced
9:20 am Liquid Biopsy in the NHS: Where Are We Now & Where Do We Need to Be
- The lung cancer “liquid first” circulating tumour DNA pilot showed the feasibility of a national service: which is cost-effective and improves outcomes
- This led to a commissioned service in this setting and in breast cancer patients becoming resistant to treatment
- Future use cases include ctDNA as a marker of minimal residual disease to both escalate and de-escalate treatment following surgery or curative radiotherapy
- Barriers remain, including setting up “business as usual” services and educating the workforce in interpreting and using these new technologies
9:40 am Transforming Patient Access in Cancer Care: A New Collaborative Era With Roche
Presentation details to be announced
10:10 am Morning Break & Refreshments
10:40 am 1:1 Meetings & Structured Networking
A dedicated window for strategic 1:1 discussions and targeted networking, enabling attendees to strengthen key relationships and have purposeful conversations that drive meaningful outcomes in precision medicine.
Fuelling Innovation in Novel Endpoints with Best Practices in Digital Pathology & Liquid Biopsy for Early Detection & Patient Enrolment
11:10 am Enabling Patient Access to Targeted Therapies with Rapid & Accessible NGS CDx Solution
- A decade of CDx development and commercialisation
- How we address the needs of rapid and accessible testing globally
- A new era of rapid decentralised global NGS CDx solutions for pharma
11:40 am Liquid Biopsy Enabling Precision Oncology Clinical Trials
- Defining ctDNA guided clinical trial designs and assay performance requirements for each
- Showcasing ctDNA as a key secondary endpoint of th e TRIDENT-1 clinical trial, a case study discussion
- Partnering on the development of a WGS MRD distributed kit
12:00 pm Establishing a Scalable Liquid Biopsy Strategy: Foundations of a Global CDx Ecosystem
- Explore the evolving landscape of NGS-based liquid biopsy adoption and the remaining barriers to equitable access
- Discover how our decentralised approach and advanced analytics enable scalable, robust, and reproducible liquid biopsy testing, supported by real-world evidence from the deployment of MSK-ACCESS® powered with SOPHiA DDM™
- Gain insights into SOPHiA GENETICS’ unique hybrid CDx development and deployment model with diagnostic partners in key markets, streamlining regulatory pathways, accelerating execution, and enabling cost-efficiency at a global scale
12:30 pm From Bench to Bedside: Ensuring Adoption of Novel Clinical Biomarkers in Bladder Cancer
- Understanding drivers and barriers for the adoption of biomarkers in a new disease area
- Sharing J&Js approach to market shaping through agility and partnerships
- Future perspectives on how to manage adoption in the evolving landscape and new CDx modalities, such as AI
1:00 pm Improving Drug Development Programs with Novel Epigenomic Insights
- A deep dive into epigenomic biomarkers within the precision oncology toolkit, and how methylation-based signatures reveal tumour biology beyond genomics
- An overview of emerging data demonstrating where epigenomic biomarkers deliver the greatest impact for patient stratification and trial enrichment
- A discussion of Guardant Health’s expanding global testing capabilities and their role in advancing epigenomics in clinical care
1:30 pm Lunch Break
1:30 pm Lunch & Learn Hosted By Foresight Diagnostics
By Invitation Only
2:00 pm 1:1 Meetings & Structured Networking
TRACK A: Biomarker Discovery & Translation
TRACK B: Clinical & CDx Development
TRACK C: Rx-Dx Commercialisation & Adoption
TRACK A: Biomarker Discovery & Translation
Leveraging Dynamic Oncology Biomarkers for Real-Time Stratification & Evidence-Based Clinical Decisions
2:30 pm Interrogating Publicly Available Datasets for Biomarker Discovery & Prioritisation
Chief Scientific Officer, Step Pharma
- Presenting a worked example of how data from human cell lines and primary tumours can be leveraged to identify biomarker of response to a compound currently in clinical development
- Discussing biomarker complexity as a consideration for clinical development
2:50 pm Strategies for Preserving Valuable Biomarkers in Blood
Medical Affairs Manager (Europe, Middle East, & Africa), BD Medical Essentials, Specimen Management
- Addressing logistical challenges in clinical trials for blood sample processing
- Implementing solutions to stabilise biomarkers at collection and simplify workflows
3:00 pm Practical Considerations For Translating Biomarkers Into Clinical Trial Assays – With Future CDx Development in Mind
Executive Director, Scientific Business Development, CellCarta
- Designing assays for clinical trials
- How novel technologies & algorithm fit into clinical setting
- Design development under ISO and IVDR support
3:30 pm Biomarkers in ADCs Light & Shade
Chief Medical Officer, Corbus Pharmaceuticals
- Why we love biomarkers
- Why we should be more careful
- Some brilliance for Netin-4 targeted ADCs and some dullness
3:50 pm Optimising Pre-Analytical Variables for ctDNA, cfRNA/miRNA, EVs & Proteins: Practical Guidance for Trial-Ready Liquid Biopsy
Senior Scientific Advisor, BioIVT
- Key pre-analytical factors that influence sensitivity and reliability across ctDNA, cfRNA/miRNA, EVs, and protein biomarkers
- Practical guidance on tube selection, centrifugation workflows, and processing timelines
- How to navigate tradeoffs when designing multi-analyte liquid biopsy protocols
- Essential QC considerations to ensure trial-ready, reproducible liquid biopsy samples
TRACK B: Clinical & CDx Development
TRACK C: Rx-Dx Commercialisation & Adoption
4:20 pm Afternoon Break & Dedicated 1:1 Meetings
TRACK A: Biomarker Discovery & Translation
TRACK B: Clinical & CDx Development
TRACK C: Rx-Dx Commercialisation & Adoption
TRACK A: Biomarker Discovery & Translation
Enhancing Clinical Planning with Reliable Biomarker Management & Pre-Analytics for Scalable Clinical Outcomes
4:50 pm Panel Discussion: Advancing Sample Management & Pre-Analytic Workflows for Robust, Reproducible Clinical Outcomes
Director of Clinical Biomarkers, Moderna
Head Precision Medicine Operations, GlaxoSmithKline
Executive Director & Head, Precision Medicine Laboratory Operations & Companion Diagnostics, Regeneron
Biomarker Samples, Logistics & Operations Officer, Resolution Therapeutics
- How can early integration of a global-ready sample and biomarker strategy into clinical design reduce downstream risk of sample or data variability?
- What are the key approaches to harmonizing pre-analytical workflows, and how can they be controlled across multi-site operations?
- What innovations in digital tools are facilitating end-to-end integrity and reproducibility?
- How are sponsors ensuring consistency in biospecimen handling when working across multiple CROs or laboratory partners?
- What level of collaboration between translational scientists, clinicians, and data teams is needed to ensure biomarker hypotheses remain viable throughout trial execution?
5:20 pm Enquire About 2026 Speaking Positions
5:50 pm Getting Laboratories Off the Critical Path
Head Precision Medicine Operations, GlaxoSmithKline
- Thinking digital – how can we plan better and reduce handoffs of data and requirements
- How to keep track of the geopolitical changes in requirements
- Managing pre-analytics should not be left to chance!
TRACK B: Clinical & CDx Development
TRACK C: Rx-Dx Commercialisation & Adoption